Epidermal growth factor receptor-targeted agents and paronychia: A US Food and Drug Administration Adverse Event Reporting System-based real-world pharmacovigilance analysis
J Am Acad Dermatol. 2026 Mar 16:S0190-9622(26)00407-X.
doi: 10.1016/j.jaad.2026.03.031.
Online ahead of print.
1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou Zhejiang, China.
2 Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
3 Department of Dermatology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Electronic address: 21618086@zju.edu.cn.
4 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou Zhejiang, China. Electronic address: jiahongyu@zju.edu.cn.